Developing targeted therapies for patients living with rare and aggressive diseases

Ayala Pharmaceuticals is developing precision medicines to target rare genetically driven cancers.

Ayala is targeting the Notch pathway, a conserved signaling pathway involved in cell proliferation, differentiation, and survival – one that plays a key role in cancer progression across multiple types of cancer.

Ayala uses companion diagnostics to specifically treat patients with Notch mutations with clinical programs in adenoid cyctic carcinoma (ACC) and desmoid (>$1B market).


Investing partner / fund: